NIH R01 · 2024
Targeting the CD73-adenosinergic pathway in head and neck cancer
Head and neck squamous cell carcinoma (HNSC) related to tobacco and alcohol consumption is aggressive and responds poorly to available therapy. Even the new PD-1/PD-L1 immune checkpoint blockade is insufficient to control progression due to other highly immunosuppressive conditions in the tumor microenvironment (TME). Compelling evidence implicates the ecto-5'-nucleotidase (NT5E) CD73 as another important immune checkpoint, as high CD73 expression in the TME of many tumors, including HNSC, is linked to poor patient survival. Several consistent TME conditions, such as hypoxia and treatment, cause an increase in extracellular (e)ATP, and CD73 serves at the last, rate-limiting step in concert…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.